Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on November 4, 2025, at 4:30 p.m. ET to report its financial results and discuss corporate progress for Q3 2025 [1] - The live audio of the webcast will be accessible on the company's Media & Investors page, with an archived version available for replay for 30 days post-event [2] Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - The company collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important cancer treatments [4]

BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its second quarter 2025 financial results and highlighted recent corporate achievements. "We have strong momentum going into the second half of 2025. We continue to focus on our three core priorities: accelerating revenu ...

Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on August 5, 2025, at 4:30 p.m. ET to report its financial results and discuss corporate progress for the second quarter of 2025 [1] - The live audio of the webcast will be accessible on the company's Media & Investors page, with an archived version available for replay for 30 days following the event [2] Pipeline and Partnerships - The company's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, social media platforms, and other channels to disseminate news, announcements, and financial performance updates [5]

Core Insights - Day One Biopharmaceuticals has appointed Dr. Michael Vasconcelles as Head of Research & Development, bringing over 25 years of oncology expertise to the company [2][3][4] - Dr. Vasconcelles will play a crucial role in advancing the company's pipeline and supporting the growth of its lead product, OJEMDA [3][5] Company Overview - Day One Biopharmaceuticals is focused on developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, addressing a significant unmet need in therapeutic development [6][7] - The company aims to redefine cancer drug development and improve outcomes for patients of all ages from the moment of diagnosis [6] Leadership and Experience - Dr. Vasconcelles has a robust background in oncology research and development, having held leadership roles at ImmunoGen, Flatiron Health, Unum Therapeutics, and Takeda [4][5] - His previous experience includes transforming ImmunoGen into a global biotech enterprise and overseeing clinical development at Genzyme [4] Strategic Goals - The company is committed to expanding its pipeline of first- or best-in-class medicines, with a focus on delivering transformative therapies for children with cancer [3][5] - Dr. Vasconcelles' leadership is expected to enhance the company's medical and scientific strategies, driving growth and innovation [3][5]

Core Insights - Day One Biopharmaceuticals reported a 16% increase in OJEMDA™ (tovorafenib) prescriptions in Q1 2025 compared to Q4 2024, with net product revenue reaching $30.5 million [1][2] - The company ended Q1 2025 with $473.0 million in cash, cash equivalents, and short-term investments [1][5] - Day One is focused on executing its objectives with urgency and fiscal discipline, aiming to create value at every organizational level [2] Financial Performance - OJEMDA net product revenue for Q1 2025 was $30.5 million, an 11% increase in U.S. revenue from Q4 2024 [2][5] - Total revenues for Q1 2025 were $30.8 million, with license revenue from ex-U.S. commercial rights amounting to $0.3 million [5][15] - Research and development expenses were $39.6 million, a slight decrease from $40.2 million in Q1 2024, while selling, general, and administrative expenses rose to $29.3 million from $26.6 million [5][15] - The net loss for Q1 2025 was $36.0 million, a reduction from a net loss of $62.4 million in Q1 2024 [5][15] Product Development and Regulatory Updates - Since its launch, OJEMDA has generated $87.7 million in net product revenue, with over 2,500 prescriptions [2] - The European Medicines Agency accepted the regulatory filing for tovorafenib in April 2025, marking a significant step for its development outside the U.S. [2] - The DAY301 clinical trial has cleared its first dose cohort in the Phase 1a portion, and the pivotal Phase 3 FIREFLY-2 trial is expected to be fully enrolled in the first half of 2026 [2] Upcoming Events - Day One will host a conference call and webcast on May 6, 2025, at 4:30 p.m. ET [1][4] - The company will participate in various upcoming conferences, including the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference and the ASCO Annual Meeting [4][5]

Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on May 6, 2025, at 4:30 p.m. ET to report financial results and discuss corporate progress for Q1 2025 [1] - The live audio of the webcast will be accessible on the Day One Investors & Media page, with an archived version available for replay for 30 days following the event [2] Pipeline and Collaborations - The company's pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, X handle, and LinkedIn page to disseminate news, announcements, and financial performance updates [5]